Nektar Update (1-18-13)

CONTINUED PROGRESS AND PIPELINE VISIBILITY. Nektar management continues to make progress across its late–stage development pipeline, relieving some investor concern for the naloxegol (NKTR-118) program – NKTR’s lead compound – under development for the treatment of opioid-induced constipation (OIC).  With renewed optimism on the ‘118 program and upcoming related catalysts, increasing appreciation of the breadth[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Dick Davis Investment Digest (1-09-13)

January 9, 2013 Top Picks for 2013 Written By Chloe Lutts Welcome to the super-sized Investment Digest Top Picks for 2013 issue. Inside this issue, you’ll find over 50 of our contributors’ very favorite investments to own this year. Plus, this year we’re bringing you an even wider selection of Top Picks through a collaboration with[…]

Posted on by

MTSL Issue #745

January 4, 2013 Below is a pdf for Issue 745 of the Medical Technology Stock Letter. [gview file=”http://50.87.166.114/wp-content/uploads/2013/03/MTSL-745-January-4-2013-2.pdf” save=”1″]    

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

OncoGenex Update (12-21-12)

OncoGenex has announced the start of PACIFIC, an investigator-sponsored, randomized Phase II trial testing OGX-427 in 80 men with metastatic castrate-resistant prostate cancer (CRPC) who are experiencing a rising PSA while receiving JNJ’s Zytiga (abiraterone acetate). The aim of the study is to determine if adding 427 to Zytiga treatment can reverse or delay treatment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Sangamo Update (1-18-13)

OUTLOOK 2013 – THE OPEN-ENDED POTENTIAL OF ZFPS SGMO’s stock has exploded since their presentation last week at the JP Morgan conference.  The company began the presentation by broadly explaining what their technology can accomplish.  The ability to actually mechanistically, physically, and permanently change a single disease related gene (monogenic) has huge potential.  SGMO’s technology[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Coronado Update (1-04-13)

Coronado Biosciences is poised for a big year in 2013. Every year we are asked to give our top pick for the year by various publications such as Dick Davis Digest.  This year we chose CNDO as our Top Pick for 2013. The company has had two pieces of good news since the last Issue.  The[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

ImmunoGen Update (1-04-13)

ImmunoGen has announced that Amgen has licensed the exclusive right to use the Company’s TAP technology to develop anticancer therapeutics to a third target, which is undisclosed.  Amgen licensed rights for two other targets in 2009 and has two compounds in clinical testing under those licenses. “We’re pleased with the interest major healthcare companies are[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Biotech Conferences

Conferences and Meetings 2019    ASCO Gastrointestinal Cancers Symposium      17-Jan-19 19-Jan-19 San Francisco, California February WORLD Symposium 4-Feb-19 8-Feb-19 Orlando, Florida ISC International Stroke Conference 6-Feb-19 8-Feb-19 Honolulu, Hawaii ASCO-GU ASCO Genitourinary Cancers Symposium 14-Feb-19 16-Feb-19 San Francisco, California AVF American Venous Forum 19-Feb-19 22-Feb-19 Rancho Mirage, CA AAAAI / WAO American Academy of Allergy, Asthma[…]

Posted on by

The Stock Advisors (1-17-13)

January 17, 2013 Top Picks for 2013 Written By John McCamant Pacira Pharmaceuticals (PCRX) is our top conservative stock recommendation for 2013. The specialty pharmaceutical company develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. The company’s drugs are based on its proprietary DepoFoam drug delivery technology. Its lead drug, Exparel, is a[…]

Posted on by

Aastrom Update (1-04-13)

Aastrom has announced that the company’s board of directors has named Dan Orlando interim CEO of Aastrom.  Mr. Orlando, who joined the company as Chief Commercial Officer in August has the experience and skills to handle the additional responsibility. Aastrom’s president and CEO Tim Mayleben is retiring but will remain an active member of the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue #744

December 21, 2012 Below is a pdf for Issue 744 of the Medical Technology Stock Letter. [gview file=”http://50.87.166.114/wp-content/uploads/2013/03/MTSL-744-December-21-2012-1.pdf” save=”1″]    

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (12-14-12)

Isis had bad news this morning and the stock is actually up. The company and its partner Genzyme announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for its marketing authorization application (MAA) for Kynamro for the treatment of patients with Homozygous[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by